logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study

Goig GA, Menardo F, Salaam-Dreyer Z, Dippenaar A, Streicher EM,  et al.
2023-06-06 • Lancet Microbe
2023-06-06 • Lancet Microbe
BACKGROUND
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...
Journal Article
|
Research

Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-08-30 • Antimicrobial Agents and Chemotherapy
2021-08-30 • Antimicrobial Agents and Chemotherapy
Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...
Journal Article
|
Research

Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study

Cox HS, Salaam-Dreyer Z, Goig GA, Nicol MP, Menardo F,  et al.
2021-11-01 • Lancet Microbe
2021-11-01 • Lancet Microbe
BACKGROUND
South Africa has a high burden of rifampicin-resistant tuberculosis (including multidrug-resistant [MDR] tuberculosis), with increasing rifampicin-monoresistant (RMR) tube...
Journal Article
|
Research

Rifampicin-monoresistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S,  et al.
2021-10-18 • Antimicrobial Agents and Chemotherapy
2021-10-18 • Antimicrobial Agents and Chemotherapy
Rifampin monoresistance (RMR; rifampin resistance and isoniazid susceptibility) accounts for 38% of all rifampin-resistant tuberculosis (RR-TB) in South Africa and is increasing. We aime...
Journal Article
|
Research

Whole genome sequencing has the potential to improve treatment for rifampicin-resistant tuberculosis in high burden settings: a retrospective cohort study

Cox HS, Goig GA, Salaam-Dreyer Z, Dippenaar A, Reuter A,  et al.
2022-02-16 • Journal of Clinical Microbiology
2022-02-16 • Journal of Clinical Microbiology
BACKGROUND
Treatment of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB), although improved in recent years with shorter, more tolerable regimens, remains largely...